INTRODUCTION
The subject is well presented and its relevance well justified. It would be interesting to add some information from literature about biomarkers, to explain the pertinence of studying them.
I would suggest to clearly identify a MAIN OBJECTIVE here. Indeed, the first aim seems to compare the prognosis of two groups (concussion and orthopedic groups), but the title does not announce this comparison.
METHODS and ANALYSIS
Page 6, line 13, Study Design : 48 hours (T0) seems to be late for withdrawing biomarkers blood sample, because the half-life of proteins already that have been studied is known to be short (a few hours maximum).
Page 7, Study Population: if I understand well, Patients with concomitant injury will not be recruited. I understand that it will help to know what is really associated to concussion compared to other injuries. But this will reduce the generalization of results.
Page 7, Study Population: Patients with history of psychiatric illness, medication use or intoxication will be excluded from this study (General Exclusion Criteria) . But the literature suggests that those characteristics could be risk factors for persistent symptoms. Why choosing to exclude those patients?
Pages 16-18, Data Analysis:
Page 17, line 6, Statistical Analysis Plan: Under « Study Outcomes » (page 9, line 46), the primary outcome stated is « symptoms at 2 weeks » and under « Population to be analyzed » (page 16, line 53), it is stated that « delayed recoverers » are defined at 2 weeks as well. So the primary outcome should be at 2 weeks (and maybe secondary outcome at 4 weeks)… Page 17, line 18: there are no information about the variables for adjustment; please add some potential confounding factors.
Page 17, line 49, methodology for impact analysis to assess the economic consequences: please give some more precisions and references about the regression modeling strategies. For example, the WHO Economic Impact Guide gives some excellent references, available on the WHO website: http://www.who.int/choice/economicburden/en/ Page18, line 39: accessibility to RedCap for patients and their family is a nice initiative to improve recruitment and to reduce lost to follow up. Congratulations for this idea! Finally, there is no mention about sample size and this is a very important issue. This sample size should be calculated using the main objective: sample size for comparison of two groups will be different from sample size for predictive modelisation. As well, it could be important to mention the estimation for the lost to followup.
ETHICS AND DISSEMINATION
Maybe mention other KT methods, like social media (as mentioned in abstract).
SIGNIFICANCE AND OUTLOOK
Very interesting study, with clinical and social significance. 
REVIEWER

GENERAL COMMENTS
The protocol is presented in a clear and thorough manner. However, I have few comments and suggestions that are listed below.
1. The authors need to be consistent regarding the term PCS (on page 6 "PCS is defined as clinically significant symptoms persisting beyond one month post-injury"). However, throughout the protocol they use the term "PCS" to indicate symptoms persisting at 2-weeks post-injury. Please, check and edit accordingly. 2. On page 17 the investigators state "Our primary outcome is PCS at 2 weeks and one-month post-injury". This is not consistent with the primary outcomes defined on page 9. 3. In the abstract, please define the acronyms "PPCS". 4. On page 3 lines 13-14, include the reference of the Bakhos article.
5. There is a significant overlap between this protocol and the previous published Take C.A.Re protocol which should be acknowledged. 6. Aim 4 (Page 17) is unclear and does not appear to be listed among the study outcomes.
VERSION 1 -AUTHOR RESPONSE
REVIEWER 1
1. ABSTRACT -It is not clear if this cohort is a new cohort comparing to Take C.A.Re study already recruiting. Please give some more clarification here or in the Methods Section.
The following sentence has been added to the method on page 6, line 27, "Because of the additional measures, the participants recruited for Take CARe Biomarkers are a separate cohort relative to the original Take CARe study. On establishing the Take VARe Biomarkers protocol, recruitment for Take CARe has ceased."
2. INTRODUCTION -The subject is well presented and its relevance well justified. It would be interesting to add some information from literature about biomarkers, to explain the pertinence of studying them. I would suggest to clearly identify a MAIN OBJECTIVE here. Indeed, the first aim seems to compare the prognosis of two groups (concussion and orthopedic groups), but the title does not announce this comparison.
To better capture the main objective of the study, the second aim has me moved to the first, which now reads, "To evaluate the contribution of acute biomarkers to delayed recovery post-concussion, tapping the key aspects of the post-injury metabolic cascade and associated brain pathology to better understand the mechanisms underlying delayed symptom recovery". The following paragraph has been modified on page 5, line 23, "Indeed, a recent systematic review published by our group10 highlights the potential utility of several blood biomarkers (e.g., GFAP, UCH-L1). Measurement of these mechanisms and their interplay, via blood biomarkers and sophisticated neuroimaging, may provide objective indices of injury severity, assist in identifying children at risk for delayed recovery, help define injury clinical phenotypes, and inform decisions regarding safe return to normal activities."
3. METHODS AND ANALYSIS -Page 6, line 13, Study Design : 48 hours (T0) seems to be late for withdrawing biomarkers blood sample, because the half-life of proteins already that have been studied is known to be short (a few hours maximum).
We acknowledge the reviewers concerns, however the T0 time point is when the participant presents to the Emergency Department and represents the earliest time point at which we would be able to obtain a blood sample. Whilst 48 hours is the maximum window for eligibility, in practice, the majority of participants present within hours of their injury. In addition, whilst the half-life of proteins that have been studied in this setting to date might be short, our non-focussed discovery approach will likely yield new proteins, with longer half-lives or whose expression might start to change closer to the 48 hour mark.
4. METHODS AND ANALYSIS -Page 7, Study Population: if I understand well, Patients with concomitant injury will not be recruited. I understand that it will help to know what is really associated to concussion compared to other injuries. But this will reduce the generalization of results.
We wanted to focus on concussion only because there are multiple variables within a concussion injury alone that can contribute to a child's outcome (e.g., age, sex, injury circumstances). Reducing concomitant injury will allow us to focus on concussion-specific effects. Further, concussion is a ubiquitous injury and we do not feel that generalizability will be a significant concern.
5. METHODS AND ANALYSIS Page 7, Study Population: Patients with history of psychiatric illness, medication use or intoxication will be excluded from this study (General Exclusion Criteria). But the literature suggests that those characteristics could be risk factors for persistent symptoms. Why choosing to exclude those patients?
As highlighted in the previous comment, we wanted to reduce the influence of severe comorbidities to more accurately examine the influence of concussion in isolation. With respect to intoxication, assessment in this context would be problematic given the overlap in profile with concussion (e.g., poor attention, slowed processing speed).
6. DATA ANALYSIS -Page 17, line 6, Statistical Analysis Plan: Under « Study Outcomes » (page 9, line 46), the primary outcome stated is « symptoms at 2 weeks » and under « Population to be analyzed » (page 16, line 53), it is stated that « delayed recoverers » are defined at 2 weeks as well. So the primary outcome should be at 2 weeks (and maybe secondary outcome at 4 weeks)…
We chose the primary outcome as PCS at 2-weeks and 1-month for two main reasons:
1) The Berlin consensus statement defines delayed recovery as symptoms persisting beyond 1-month post-injury. We therefore thought it would be prudent to include this time point as a primary outcome to examine recovery.
2) Based on our pilot data, 50% of our sample had returned to pre-injury levels at 2-weeks and we wanted to examine factors that contributed to their recovery.
7. DATA ANALYSIS -Page 17, line 18: there are no information about the variables for adjustment; please add some potential confounding factors.
Our pilot data suggests that child age is the only relevant 'non-modifiable' factor in predicting persisting PCS. With this, we have included this in the statistical analysis plan.
8. DATA ANALYSIS -Page 17, line 49, methodology for impact analysis to assess the economic consequences: please give some more precisions and references about the regression modeling strategies. For example, the WHO Economic Impact Guide gives some excellent references, available on the WHO website: http://www.who.int/choice/economicburden/en/ We have included additional references for assessing costs of child concussion and factors predicting high cost as the reviewer suggested.
9. DATA ANALYSIS -Page18, line 39: accessibility to RedCap for patients and their family is a nice initiative to improve recruitment and to reduce lost to follow up. Congratulations for this idea! Thank you! 10. DATA ANALYSIS -Finally, there is no mention about sample size and this is a very important issue. This sample size should be calculated using the main objective: sample size for comparison of two groups will be different from sample size for predictive modelisation. As well, it could be important to mention the estimation for the lost to follow-up.
We have included a 'Sample size estimation' subsection to the Data Analysis section of the manuscript.
ETHICS AND DISSEMINATION -Maybe mention other KT methods, like social media (as mentioned in abstract).
The last sentence of the ETHICS AND DISSEMINATION paragraph has been amended and now reads, "Results from this study will be disseminated at regional and international conferences, in peerreviewed journals, and via popular media (e.g., social media)." REVIEWER 2
1. The Bakhos estimate of 502,000 concussions over 5 years (8-19 years) is an order of magnitude less than many of the other estimates (Meehan, etc.). This would only be 100,000 concussions per year in the USA. Additionally, the Bakhos paper is not referenced
The final sentence of the first paragraph on the introduction (page 4, line 16) has been amended and now reads, "Meehan4 and colleagues found that approximately 144,000 paediatric patients present to Emergency Departments each year with a concussion in the United States."
2. Yeates, et al. recently published a protocol in BMJ Open examining neurobiological and psychosocial markers to concussion recovery. This is a multi centre trial with 700 mTBI and 300 OI.
(http://bmjopen.bmj.com/content/7/7/e017012.long). Given the significant overlap with imaging, use of orthopaedic controls and biomarkers (genetic studies), it would be very much worth referencing this protocol (especially since it is the same journal -BMJ Open).
Yeates' study has been referenced on Page 19, line 18, which now reads, "Child concussion is a major health problem of significant cost and concern to parents, schools, sporting association and the wider community. Recent media and academic45 focus has heightened awareness of potential risks for concussion, to the extent of consideration of excluding children from contact sports." Also, referenced on page 18, line 49, "The present study is being conducted at a single site, The Royal Children's Hospital (a paediatric tertiary hospital). While the presentation of concussion is significant at RCH (~1,000 per year), it is possible that this will limit the recruitment options relative to other studies (e.g., A-CAP45) and reduce statistical power."
3. The definition of PCS (page 6) is a bit vague "clinically significant symptoms persisting beyond one month post-injury". While this is defined in more detail later, I would expand further upon this here. For example, the previously published Take C.A.Re protocol (BMJ Open 2016) uses >=3 symptoms compared with baseline; this study now proposes to use 2 or more. I would either discuss this earlier (I know it is in methodological consideration section), or I would cross-reference it (e.g., "See Methodological Considerations section for further explanation of PCS definition").
The following sentence was added to the Definitions sub-section of the Methods and Analysis section (page 6, line 56), "(See Methodological Considerations section for further explanation of PCS definition)".
4. Given that the Take C.A.Re protocol has already been published in the BMJ Open, this new publication is append the study to add the biomarkers. This should perhaps be introduced more in the background. This is especially important since recruitment is still on-going for Take C.A.Re.
See response to Reviewer 1, question 2. In addition, the following sentences have been added to page 6, line 10, "Take CARe Biomarkers incorporates the elements from the original study and substantially expands and adds novel aspects (e.g., MRI, blood biomarkers, and extensively expanded clinical measures). As such, it can be considered a separate study as opposed to an addendum to Take CARe."
5. The sample size has not been justified for the proteomic blood biomarker study (30 concussion, and 30 orthopedic samples). There will be a multiplex of 5 cytokines, 2 CVD, 1 HCVD, 3 Neurogenerative and 4 Neurological. This is a total of 15 exploratory biomarkers. Given the age range (5-19) and sex differences (male and female), even if the PCSI categories were used rather than actual ages (5-8 male/female, 9-12 male/female, 13-18 male/female), this would yield 6 categories. Are 30 samples enough to denote differences between groups for biomarkers? The sample size needs to be justified further. Is this simply a convenience sample or pilot study? Or will this be a definitive study? If it is a pilot study, this should be added to the title and/or the abstract. NOTE: this clarification should not preclude publication (especially since BMJ Open certainly publishes protocols for pilot studies.)
The sample size of n=30 per group is very much comparable to the studies that have been performed to date in this setting, as outlined in our recent systematic review (Lugones M, et al). Whilst a specific power calculation would be the ideal scenario, this is not possible, because of the fact that there has to date not been a study that has been as detailed and focused on as many markers as we will be investigating, in combination with a control and a study group approach. In addition, the evidence related to some of the blood markers studied to date has been contradictory, making a sample size calculation difficult to perform. This will be the largest and the most comprehensively designed blood biomarker study in the setting of paediatric concussion to date and will as such be a definitive study.
6. The same sample size concern exists for the power calculation for the imaging section. Power analysis for neuroimaging is complex as the analysis is modality and analysis technique specific. Consequently a study can be powered to detect group/treatment differences for tract modelling in diffusion imaging but underpowered to detect findings for task based fMRI analysis. Typically, power estimations are made with reference to the magnitude of group difference /treatment effects in existing literature. On the basis of the published neuroimaging studies to date we anticipate that the 50 participants we plan to recruit will provide sufficient power to identify robust group differences/treatment effects. While we acknowledge the current state of methodological heterogeneity within the concussion neuroimaging literature, the present study represents a considerable methodological improvement and will certainly make a substantial contribution to the literature. However, we note the reviewer's concerns and we have changed the description of the imaging component to "exploratory". 7. Under methodical considerations/limitations, consider adding a discussion re: single centre and potentially underpowered Page 18, line 49 now reads, "The present study is being conducted at a single site, The Royal Children's Hospital (a paediatric tertiary hospital). While the presentation of concussion is significant at RCH (~1,000 per year), it is possible that this will limit the recruitment options relative to other studies (e.g., A-CAP45) and reduce statistical power."
8. The following sentence was added to the Ethics and Dissemination section (page 18, line 55), "Written parental consent is obtained for all participants and written participant consent is obtained for participants aged 13 years and older. All participants can withdraw consent and any time and younger participants are asked to assent to all aspects of the study (e.g., MRI)."
Statistics: a. Analysis plan is adequate, but further discussion re: sample size is required (see above).
Included, see Sample Size Estimation on page 18
References: b. See suggestions re: references above. (Consider Yeates, Barlow and Mersov).
The suggested reference has been added 5. There is a significant overlap between this protocol and the previous published Take C.A.Re protocol which should be acknowledged.
See response to Reviewer 2, question 4 6. Aim 4 (Page 17) is unclear and does not appear to be listed among the study outcomes This is correct, it was a typo and has been deleted.
VERSION 2 -REVIEW
REVIEWER
Roger Zemek
Children's Hospital of Eastern Ontario, Ottawa, Canada REVIEW RETURNED 06-Oct-2018
GENERAL COMMENTS
In this revision, the authors have adequately addressed the comments and questions from the original peer review and is acceptable for publication.
